Episode notes
This week, our subjects are a silica nanoparticle gene delivery system in a conversation with Nigel Theobald, CEO of N4 Pharma, and a point-of-care diagnostics system for urinary tract infections developed by Welsh company Llusern Scientific. We spoke with the company's co-founder and CEO, Dr Emma Hayhurst.
Interview times:
03:00 N4 Pharma
24:45 Llusern Scientific
N4 Pharma
N4 Pharma is a UK biotech company developing a silica nanoparticle gene delivery system called Nuvec.
Nuvec is being used to enable advanced therapies for cancer and other diseases. N4 Pharma has developed a pre-clinical RNA therapeutic, N4 101, which is a patient-friendly ...
Keywords
biotechbiotechnologynanoparticlesAMRantimicrobial resistanceWalesLlusern ScientificN4 PharmaUTIurinary tract infectiongene delivery